CureVac N.V.
NASDAQ:CVAC
Overview | Financials
Company Name | CureVac N.V. |
Symbol | CVAC |
Currency | USD |
Price | 4.07 |
Market Cap | 912,925,420 |
Dividend Yield | 0% |
52-week-range | 2.215 - 5.28 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Alexander Zehnder M.B.A., M.D. |
Website | https://www.curevac.com |
An error occurred while fetching data.
About CureVac N.V.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD